FDA and FTC endorsement rules for medspa, aesthetic and pharma marketing

Who regulates what — the FDA, FTC and state overlay

The Food and Drug Administration regulates the manufacture and labelling of drugs, biologics and devices under the Federal Food, Drug, and Cosmetic Act. Prescription drug advertising is regulated at 21 CFR 202.1, and device labelling and promotion at 21 CFR 801. Misbranding — including false or misleading labelling or advertising — is prohibited under 21 USC 352.

The Federal Trade Commission regulates advertising truthfulness and endorsements under 15 USC 45. The FTC Endorsement Guides at 16 CFR Part 255 provide the operational framework for testimonials, expert endorsements, influencer marketing and consumer reviews. The 2023 update was the first substantive revision since 2009 and it materially tightened enforcement expectations.

State medical boards regulate the practice of medicine and the advertising conduct of licensed practitioners. Board rules can be stricter than either FDA or FTC — some states restrict specialty designation, some require credential disclosures on every ad, and many restrict testimonials in specific ways.

The 2023 Endorsement Guides revision — what actually changed

The June 2023 revision to 16 CFR Part 255 tightened four areas relevant to healthcare marketing.

1. Material connection disclosure

Any relationship between the endorser and the advertiser that could affect the weight consumers give the endorsement must be clearly and conspicuously disclosed at the point of the endorsement. That means the disclosure appears where the endorsement appears — not in a linked bio, a scrollable footer, or a hover state. Free products, discounts, family relationships, employment, and financial arrangements all qualify as material connections.

2. Liability chain

The revised guides expressly reach advertisers, endorsers, and intermediaries. An advertising agency, a media buyer, or a talent broker who facilitates a non-compliant endorsement is potentially liable in its own right. Contractual language passing all liability to the endorser does not close the loop for the agency.

3. Consumer reviews

Solicited reviews from incentivised customers must disclose the incentive. Fake reviews, review suppression, and review platforms that filter negative feedback are treated as unfair and deceptive practices. The FTC's separate 2024 rule on fake reviews and testimonials (16 CFR Part 465, effective October 2024) adds a distinct civil-penalty basis.

4. Expert endorsements

An expert endorsement must be based on an appropriate examination or testing of the product, and the expert's qualifications must genuinely give the endorsement the value it implies. A physician endorser must have expertise commensurate with the claims made in the endorsement, and the endorsement must rest on evaluation rather than compensation.

Where enforcement actually lands

FTC enforcement in the aesthetic and health-adjacent space has focused on unsubstantiated efficacy claims, hidden material connections in influencer campaigns, review manipulation, and endorsement disclosures that do not meet the clear-and-conspicuous standard. The FDA's warning-letter catalogue in the aesthetic and regenerative space repeatedly targets promotional claims that stray outside approved indications and stem-cell providers making unproven efficacy claims.

Enforcement tends to arrive by two paths: consumer complaints that route through the FTC's consumer sentinel database, and competitor-driven complaints via industry-association referral (particularly the ASAPS/ASPS aesthetic groups). Either path can trigger an investigation, and the discovery burden of an investigation typically dwarfs the cost of proactively building the substantiation folder before the ad runs.